Personalized vasopressor therapy for septic shock
Official title: Personalized vasopressor therapy in patients with septic shock
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11394826 · Data updated 2026-11-12
A clinician-scientist at Cleveland Clinic aims to tailor vasopressor treatment for septic shock patients using patient-specific factors.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 1, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $177,463 |
| NIH project number | 5K08GM147806-05 |
| Project ID | NIH-11394826 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with septic shock treated in the intensive care setting who are candidates for vasopressor therapy.
✕Less likely to help
Patients not presenting with septic shock or those for whom vasopressor therapy is not indicated.
What this research studies
This project uses patient data to build models that predict how individuals with septic shock will respond to initial and adjunctive vasopressor therapy. The work plans to apply machine learning to forecast treatment response and to create a bedside decision tool to optimize vasopressor choices. By testing these models in a real clinical setting, the team hopes to reduce mortality and improve stability in septic shock patients. The study will translate the models into practical steps clinicians can use at the patient’s bedside.
Why it matters
Potential benefit: If successful, it could personalize vasopressor therapy to reduce deaths and complications in septic shock.
How similar studies have gone: Preliminary data suggest variability in vasopressor response and potential benefits from personalized approaches; broader validation is needed.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Bauer, Seth — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Bauer, Seth
Related research
Other NIH-funded projects on the same topics.
-
Pragmatic midodrine trial to reduce ICU vasopressor use in septic shock
A practical, patient-focused trial tests whether taking oral midodrine can lessen the need for IV vasopressors and shorten ICU stays for people with sepsis-related low blood pressure.
-
Angiotensin-based treatment strategy in septic shock
A clinical trial will compare giving Angiotensin II versus standard norepinephrine to support blood pressure in septic shock patients, aiming to improve outcomes.
-
Percutaneous stellate ganglion stimulation to support blood pressure in septic shock
A small, portable neuromodulation device would be tested to help people with septic shock maintain blood pressure while doctors adjust medicines.
-
Macrophage metabolism and septic shock in humans
A study at Boston Children’s Hospital will explore how immune cells’ metabolism affects severe infection (septic shock) and whether targeting this metabolic pathway could help patients.
-
Blood transfusions and organ failure in children with septic shock
This project looks at how a child’s circulation, immune status, and the type of red blood cells given affect recovery and organ problems during septic shock in young children.
-
How immune cell metabolism affects septic shock
This study is looking at how the way immune cells use energy affects the body's reaction to septic shock, which can happen after a severe infection, and it hopes to find new ways to help people with sepsis feel better by reducing harmful inflammation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.